Drug Profile
NN 9925
Alternative Names: NN9925Latest Information Update: 12 Nov 2013
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 12 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (IV)
- 12 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in United Kingdom (PO)
- 27 Aug 2010 Novo Nordisk completes enrolment in a phase I trial (NCT01087645) in the UK